# Body Composition Analysis and Time to Emergence From Remimazolam

> **NCT05512559** · — · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 90 (estimated)

## Conditions studied

- Remimazolam
- Body Composition

## Interventions

- **DEVICE:** body composition analysis

## Key facts

- **NCT ID:** NCT05512559
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-05
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-03
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512559, "Body Composition Analysis and Time to Emergence From Remimazolam". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05512559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*